share_log

加科思-B(01167)完成泛KRAS抑制剂JAB-23E73 I/IIa期临床试验在中国的首例患者给药

Zhitong Finance ·  Nov 25, 2024 01:04

加科思-B(01167)发布公告,公司自主研发的泛KRAS抑制剂 JAB-23E7...

智通财经APP讯,加科思-B(01167)发布公告,公司自主研发的泛KRAS抑制剂 JAB-23E73在中国完成I/IIa期临床试验首例患者给药。

KRAS广泛存在于多种肿瘤突变,约23%-25%的癌症患者带有KRAS突变,全球每年新增约270万带有KRAS相关突变的肿瘤患者有望从泛KRAS抑制剂中获益。

JAB-23E73可同时抑制KRAS的活性及非活性状态的KRAS,并对HRAS、NRAS 无明显抑制。作为口服KRAS抑制剂,JAB-23E73的临床前资料展现了良好的药代动力学特性。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 273

Recommended

Write a comment

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.